Kura Oncology (NASDAQ:KURA) drew attention as its oral menin inhibitor gained traction in AML, keeping the biotech in focus ...
Panelists discuss how fitness assessment has evolved beyond traditional age cutoffs to incorporate comprehensive geriatric assessments, frailty measures, and individualized evaluations, while ...
Randomization within Beat AML assigned 169 patients to AV28 or AV14, with CR within two cycles as the noninferiority primary ...
PRESS RELEASECHARM Therapeutics announces formation of Clinical Advisory Board to support advancement of CHM-029, its next-generation menin ...
Moleculin Biotech ( (MBRX)) just unveiled an announcement. Moleculin Biotech has revealed promising findings showcasing Annamycin’s potential to combat acute myeloid leukemia (AML) resistant to ...
Acute myeloid leukemia (AML), an aggressive and often fatal blood cancer, has long resisted a class of drugs called proteasome inhibitors, which work well in multiple myeloma. A new study by ...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) o ...
InnoCare receives China NMPA approval for phase III trial of mesutoclax with azacitidine versus venetoclax with azacitidine to treat naive AML: Beijing Thursday, August 20, 2026, ...
A study published in Nature Cell Biology reports a new vulnerability in acute myeloid leukemia (AML) that might lead to novel ...
Nicole Schultz was treated for acute myeloid leukemia as a teenager. Two decades later, chronic graft-versus-host disease and ongoing survivorship monitoring remain part of her care. No one she knew ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results